Et studie til evaluering af farmakokinetik (PK) og sikkerhed af subkutant (SC) administreret ublituximab ved forskellige injektionssteder og relativ biotilgængelighed via autoinjektor (AI) versus sprøjte subkutant hos deltagere med multipel sklerose (MS)
En fase 2, multicenter, undersøgelse til evaluering af farmakokinetik og sikkerhed af subkutant ublituximab administreret på forskellige injektionssteder og relativ biotilgængelighed via autoinjektor versus sprøjte hos patienter med multipel sclerose
The purpose of this study is to evaluate the PK and safety of ublituximab SC at different sites of administration and relative bioavailability of ublituximab SC administered with a prefilled pen versus syringe.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: TG Therapeutics Clinical Support Team
- Telefonnummer: 1-877-575-8489
- E-mail: clinicalsupport@tgtxinc.com
Studiesteder
-
-
-
Bihać, Bosnien-Hercegovina, 77000
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Mostar, Bosnien-Hercegovina, 88000
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Sarajevo, Bosnien-Hercegovina, 71000
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Tuzla, Bosnien-Hercegovina, 75000
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Zenica, Bosnien-Hercegovina, 72000
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Rustavi, Georgien, 3700
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgien, 101
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgien, 114
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgien, 159
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgien, 179
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgien, 0160
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Shtip, Nordmakedonien, 2000
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Skopje, Nordmakedonien, 1000
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Bydgoszcz, Polen, 85-796
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Katowice, Polen, 40-686
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Katowice, Polen, 40-568
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Kielce, Polen, 25-726
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Krakow, Polen, 31-826
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Lodz, Polen, 90-324
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Olsztyn, Polen, 10-561
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Poznan, Polen, 61-853
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Warsaw, Polen, 04-141
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Zabrze, Polen, 41-800
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Belgrade, Serbien, 11000
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Kragujevac, Serbien, 34 000
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Chernihiv, Ukraine, 14001
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Chernihiv, Ukraine, 14029
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Ivano-Frankivsk, Ukraine, 76018
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Ivano-Frankivsk, Ukraine, 76493
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Ivano-Frankivsk, Ukraine, 76008
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 2000
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 2091
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 3037
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 3110
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 4050
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 4211
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Lviv, Ukraine, 79010
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Lviv, Ukraine, 79029
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Odesa, Ukraine, 65009
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Poltava, Ukraine, 36011
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Ternopil, Ukraine, 46014
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Uzhhorod, Ukraine, 88018
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Vinnytsia, Ukraine, 21001
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
Vinnytsia, Ukraine, 21009
- Rekruttering
- TG Therapeutics Investigational Trial Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Diagnosis of relapsing multiple sclerosis (RMS) (2017 Revised McDonald criteria).
- Expanded Disability Status Scale (EDSS) score less than or equal to (≤) 5.5 at screening.
- Neurologically stable for more than (>) 30 days prior to screening and Day 1.
- Female participants of childbearing potential must consent to use an effective method of contraception from consent and for 6 months after the last dose of ublituximab.
Exclusion Criteria:
- Primary-progressive multiple sclerosis (PPMS) or inactive secondary progressive multiple sclerosis (SPMS).
- Active chronic disease of the immune system other than MS or immunodeficiency syndrome.
- Participants with significantly impaired bone marrow function or significant leukopenia or thrombocytopenia.
- Participants who received any approved therapy to treat MS within 5 half-lives of the medication prior to screening.
- Treatment with any investigational agent within 5 half-lives of the investigational drug prior to screening.
- Females who are pregnant or nursing.
Note: Other protocol-specified Inclusion/Exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Part 1: Ublituximab SC
Participants will receive ublituximab SC, using a syringe at one of three different sites of administration. |
Administered as an SC injection by a syringe.
Andre navne:
Administered as an SC injection by prefilled pen.
Andre navne:
|
|
Eksperimentel: Part 2: Ublituximab SC
Participants will be randomized to receive ublituximab SC using either the prefilled pen or a syringe. |
Administered as an SC injection by a syringe.
Andre navne:
Administered as an SC injection by prefilled pen.
Andre navne:
Ublituximab will be administered as an SC injection by prefilled pen. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Part 2: Area under the curve (AUC) at Steady State [AUCss] of Ublituximab
Tidsramme: Up to Week 12
|
Up to Week 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Del 1: Plasmakoncentrationer af Ublituximab
Tidsramme: Op til uge 24
|
Op til uge 24
|
|
Antal deltagere med behandlingsrelaterede bivirkninger (TEAEs)
Tidsramme: Op til uge 120
|
Op til uge 120
|
|
Del 2: Procentdel af deltagere, der rapporterer deres tilfredshedsniveau med SC-administrationsmetoden for ublituximab, vurderet via Therapy Administration Satisfaction Questionnaire-Subcutaneous (TASQ-SC)
Tidsramme: Op til uge 96
|
Op til uge 96
|
|
Part 2: Minimum Plasma Concentration at steady state (Cminss) of Ublituximab
Tidsramme: pre-dose and at multiple timepoints post-dose up to Week 120
|
pre-dose and at multiple timepoints post-dose up to Week 120
|
|
Maximum Plasma Concentration at steady state (Cmaxss) of Ublituximab
Tidsramme: pre-dose and at multiple timepoints post-dose up to Week 120
|
pre-dose and at multiple timepoints post-dose up to Week 120
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- TG1101-RMS-SC201
- 2025-523757-33-00 (Anden identifikator: EU CT Number)
- 2025 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .